Newbury Pharmaceuticals AB Financial Flexibility Index
Newbury Pharmaceuticals AB financial flexibility index. Newbury Pharmaceuticals AB (NEWBRY) has a Financial Flexibility Index of 0.05x as of February 2026. Free cash flow of Skr2.26 Million (operating CF Skr2.26 Million minus capex Skr0.00) represents 0% of total liabilities (Skr45.96 Million). See Newbury Pharmaceuticals AB (NEWBRY) free cash flow to measure how efficiently the company converts operating cash flow to free cash.
Financial Flexibility Index
Free Cash Flow
Total Liabilities
Capital Expenditures
Financial Flexibility Index of Newbury Pharmaceuticals AB (2021–2024)
Financial flexibility index of Newbury Pharmaceuticals AB from 2021 to 2024. Historical Financial Flexibility Index trend for Newbury Pharmaceuticals AB across 4 annual periods. Check NEWBRY operating cash flow to net income to evaluate the quality of earnings relative to operating cash generation.
Newbury Pharmaceuticals AB Financial Flexibility Index by Year (2021–2024)
Newbury Pharmaceuticals AB financial flexibility index by year from 2021 to 2024. Year-by-year free cash flow to debt coverage for Newbury Pharmaceuticals AB. For the full cash flow conversion analysis, see Newbury Pharmaceuticals AB cash flow conversion.
| Year | Flexibility Index | Free Cash Flow (SEK) | Operating CF | Total Liabilities | YoY Change |
|---|---|---|---|---|---|
| 2024 | -0.53x | Skr-20.80 Million | Skr-23.71 Million | Skr38.95 Million | ▲ +43.8% |
| 2023 | -0.95x | Skr-22.36 Million | Skr-23.23 Million | Skr23.54 Million | ▼ -283.4% |
| 2022 | 0.52x | Skr9.40 Million | Skr-15.00 Million | Skr18.14 Million | ▼ -88.2% |
| 2021 | 4.38x | Skr19.02 Million | Skr-4.07 Million | Skr4.34 Million | — |